ALVR Stock Summary and Trading Ideas (Allovir | NASDAQ:ALVR)

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Allovir trades on the NASDAQ stock market under the symbol ALVR.

As of January 29, 2025, ALVR stock price climbed to $9.75 with 5,818 million shares trading.

ALVR has a beta of -0.68, meaning it tends to be less sensitive to market movements. ALVR has a correlation of 0.02 to the broad based SPY ETF.

ALVR has a market cap of $49.15 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ALVR traded as high as $236.67 and as low as $7.96.

The top ETF exchange traded funds that ALVR belongs to (by Net Assets): VTI, VXF, FESM.

ALVR has underperformed the market in the last year with a return of -40.3%, while the SPY ETF gained +24.9%. In the last 3 month period, ALVR fell short of the market, returning -50.4%, while SPY returned +4.0%. However, in the most recent 2 weeks ALVR has outperformed the stock market by returning +6.0%, while SPY returned +3.4%.

ALVR support price is $8.97 and resistance is $10.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALVR shares will trade within this expected range on the day.